Artificial intelligence readiness involves much more than upgrading technology. For laboratories operating in regulated environments, it requires connected workflows, trusted data, effective human oversight, and compliance built into systems from the outset. Fragmented processes and disconnected platforms can undermine AI performance while creating challenges around governance, auditability, and regulatory compliance.

In this GEN podcast, an expert from LabVantage explores how regulated laboratories can build this foundation, break down data silos, and prepare for AI adoption in clinical and commercial settings. The discussion examines the technological, operational, and governance practices needed to move AI from experimentation into regulated laboratory workflows.

Podcast Guest:

Matthew Grulke
Director of Manufacturing,
Chief Technology Officer
LabVantage Solutions

Produced with support from:

The post Beyond the Technology: AI Readiness in Regulated Laboratories appeared first on GEN – Genetic Engineering and Biotechnology News.

Aurora Therapeutics, a startup focused on building personalized gene-editing drugs, has scrapped its lead program and slashed staff, just seven months after it launched, STAT has learned. 

A company spokesperson declined to say how many employees were laid off, or whether any of the startup’s three-person leadership team would stay on. Aurora’s chief scientific officer left the company earlier this year. 

The company appears to have been undercut by Beam Therapeutics, a larger and more established competitor. Just a month after Aurora launched, Beam announced it was already advancing its own set of custom gene editors for the exact same disease. 

Continue to STAT+ to read the full story…

​Read More

The anti-TL1A antibody from Merck’s 2023 Prometheus buy delivered positive mid-stage results in a skin condition but failed in a certain type of lung disease, the Big Pharma revealed alongside second-quarter earnings.